Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cienne Morton

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Medicine (London, England)|January 25, 2023
Next-generation sequencing and molecular therapyCienne Morton, Debashis Sarker, Paul Ross
British Journal of Cancer|March 24, 2023
Revitalising cancer trials post-pandemic: time for reformCienne Morton, Richard Sullivan, Debashis Sarker, et al.
Nature Cancer|January 3, 2024
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1<sup>+</sup> T cells with implications for cancer immunotherapyDaniel Davies, Shraddha Kamdar, Richard Woolf, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
Nature Cancer|May 31, 2022
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancerYin Wu, Dhruva Biswas, Ieva Usaite, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid TumorsJia Liu, Anna R Minchom, Alastair Greystoke, et al.
Journal for Immunotherapy of Cancer|June 15, 2023
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy studySophie Papa, Antonella Adami, Michael Metoudi, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Medicine (London, England)|January 25, 2023
Next-generation sequencing and molecular therapyCienne Morton, Debashis Sarker, Paul Ross
British Journal of Cancer|March 24, 2023
Revitalising cancer trials post-pandemic: time for reformCienne Morton, Richard Sullivan, Debashis Sarker, et al.
Nature Cancer|January 3, 2024
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1<sup>+</sup> T cells with implications for cancer immunotherapyDaniel Davies, Shraddha Kamdar, Richard Woolf, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
Nature Cancer|May 31, 2022
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancerYin Wu, Dhruva Biswas, Ieva Usaite, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid TumorsJia Liu, Anna R Minchom, Alastair Greystoke, et al.
Journal for Immunotherapy of Cancer|June 15, 2023
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy studySophie Papa, Antonella Adami, Michael Metoudi, et al.
Pageof 1